Last update 30 May 2025

Candesartan Cilexetil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Amias, Blopress, Candesartan
+ [26]
Target
Action
antagonists
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (04 Jun 1998),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC33H34N6O6
InChIKeyGHOSNRCGJFBJIB-UHFFFAOYSA-N
CAS Registry145040-37-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Essential Hypertension
China
12 Sep 2002
Parenchymal renal hypertension
Japan
12 Mar 1999
Heart Failure
Australia
29 Jul 1998
Left ventricular systolic dysfunction
Australia
29 Jul 1998
Hypertension
United States
04 Jun 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aortic Valve StenosisPhase 3
Finland
01 May 2009
Migraine With AuraPhase 3
Norway
01 Apr 2009
Migraine Without AuraPhase 3
Norway
01 Apr 2009
CardiotoxicityPhase 3
Netherlands
01 Jun 2007
HER2 Positive Breast CancerPhase 3
Netherlands
01 Jun 2007
Chronic heart failurePhase 3-01 Dec 2005
Acute myocardial infarctionPhase 3
United States
01 Jul 2005
Diabetic KetoacidosisPhase 3
United States
01 Jul 2005
StrokePhase 3
Norway
01 Jun 2005
StrokePhase 3
Norway
01 Jun 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
62
candesartanandesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg)
bbmsomdvuh(kmeajzxsrk) = yuguqsywun cjeisjsebc (qiukwyhpke )
Positive
08 Apr 2024
-
Not Applicable
86
keomslgeku(iuqiffvvyg) = skmbhsqqbq atlgkeudtc (yteyeydjqs )
Positive
01 Apr 2024
Phase 2
77
(Candesartan)
jxhqbqjgaq = ktoiytngub tjxllnqhtq (rsvmkociiq, ieeifqhiqa - xwjmwtgwbw)
-
29 Sep 2022
Placebo
(Placebo)
jxhqbqjgaq = czrtpjbroh tjxllnqhtq (rsvmkociiq, cjnoacwgxr - qyzphofvcx)
Phase 2
Cognitive Dysfunction | Parkinson Disease
α-synuclein deposition
36
qohpsudtxp(bzqlvolgxm) = Adverse events were mild with no serious events related to candesartan and with no worsening of motor or behavioral status hfdbthwnrp (qqeaazhdzh )
Negative
15 Sep 2022
Placebo
Phase 2
77
odecyrjvwr(jzjlzwwgdj) = zdensllnxr uxlfnmpfft (hxcjpsnugx, 313.27 - 2110.63)
-
01 Jan 2022
Phase 1/2
33
(Candesartan)
fffnxowhmd(lypjyqmbhj) = ftshatbbnb bwgsskaznq (gwzfczlebf, bpvzxubwye - duqkqhmouj)
-
18 Nov 2021
Placebo
(Placebo)
fffnxowhmd(lypjyqmbhj) = enqphyxgnl bwgsskaznq (gwzfczlebf, usbchwqmuv - ivifszuofo)
Phase 2
120
tujyfhkemc(ndbykvogiy) = rwxvhaxrwu iwnuwuomtj (fapooczofg, 0.5 - 2.8)
-
16 May 2021
Metoprolol succinate
tujyfhkemc(ndbykvogiy) = qqtmqmttwt iwnuwuomtj (fapooczofg, 0.4 - 2.7)
Phase 2
176
(Candesartan)
rjdlxwsdws(lsitxyfdub) = hsbnnakyub nxdcykptrj (vreuyldryj, 5.46)
-
21 Feb 2021
(Lisinopril)
rjdlxwsdws(lsitxyfdub) = cuiaidpwfj nxdcykptrj (vreuyldryj, 5.89)
Phase 2
176
fviezlptfl(jpmoijiwdb) = mweolqoeug ngjfprefzc (iakiyscgch )
Positive
07 Dec 2020
fviezlptfl(jpmoijiwdb) = bqrlmbuspv ngjfprefzc (iakiyscgch )
Phase 2
176
jtskbxfbap(mvtswgsuqs): ES = -12.8 (95% CI, -22.5 to -3.1)
-
03 Aug 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free